诺瓦瓦克斯医药(NVAX)早盘股价遭遇重挫,一度大跌29.76%,报收低于52.28美元。导致该公司股价大跌的主因或许是最新来自美国FDA的一则不利消息。
据路透社报道,美国FDA已暂时叫停了诺瓦瓦克斯新冠和流感联合疫苗以及独立流感疫苗两项临床试验。FDA暂停这两项重要疫苗试验的原因是由于一名受试者出现了严重不良反应。
FDA的这一决定无疑将拖延诺瓦瓦克斯这两款疫苗产品上市时间,并引发投资者对公司疫苗研发前景的担忧。随着不确定性因素增加,投资者做出了抛售该股的操作,导致该公司盘前股价出现重挫。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.